• Press Release

BIA response to conclusion of NICE methods and processes review

The National Institute for Health and Care Excellence (NICE) has published its conclusions to its review of its methods and processes for Health Technology Assessments. 

UK Life Sciences innovation highlighted by the Prime Minister at global healthcare investment conference

• Multiple UK deals and investments highlighted at key year opening global life science investment conference • Prime Minister Boris Johnson makes keynote address, highlighting strength of UK ecosystem to global investment community

A new era for the BIA as it announces new Chair and appointments to the Board plus key new hires

Following the BIA Annual General Meeting, the Association has announced its next Chair and members who have been elected to its Board of Directors. The AGM took place on Tuesday 19th October and the new board members were voted for by the BIA’s membership in the weeks leading up to the meeting

BIA reacts to £400m investment in the UK by Fujifilm Diosynth Biotechnologies

Reacting to news that Fujifilm Diosynth Biotechnologies will be investing £400m into their UK manufacturing operation Steve Bates OBE, Chief Executive of the Bioindustry Association said

The BioIndustry Association and Kidney Research UK announce new 2022 Charity of the Year partnership

The BioIndustry Association (BIA) is delighted to announce Kidney Research UK as its charity partner for 2022. Kidney disease affects three million people in the UK with 20 people developing kidney failure each day. The charity undertakes research to end kidney disease, offering kidney patients and their families hope for the future. The partnership aims to raise funds, increase awareness of kidney health, and promote kidney research to the life sciences ecosystem.

Ensuring patient access to cell and gene therapies: The case for an innovative payment model

The BioIndustry Association (BIA) has today launched Ensuring patient access to cell and gene therapies: The case for an innovative payment model. The report, which has been produced with the support of the BIA’s Cell and Gene Therapy Advisory Committee, explores the potential benefits of cell and gene therapies for patients, the challenges they face in the current system and some of the solutions being explored in other countries.

BIA responds to 2021 Autumn Budget

Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA), said: “It is thanks to the UK’s life sciences sector, which has developed essential vaccines, diagnostics and medicines to enable to re-opening of our economy, that the Chancellor was able to make important spending commitments in this Budget, which we welcome.

UK biotech sector enjoys record year of investment

A record £3 billion has been raised by the UK biotech and life science sector in the first three quarters of 2021, according to new data released today by the BioIndustry Association (BIA) and Clarivate. With £576m raised between June and the end of August, fundraising in 2021 has already surpassed the previous record year of 2020, when £2.8 billion was raised, with another three months of the year left to go.

BIA launches Comprehensive Spending Review priorities to turn UK into a life sciences superpower

The BioIndustry Association (BIA) has today launched its recommendations for the Comprehensive Spending Review, the report ‘Becoming a life sciences superpower’, explains the policies that the Government can implement to turbo charge growth in the innovative UK biotech and life sciences sector.

New report reveals strength of the UK’s thriving genomics sector

The BioIndustry Association (BIA), the Wellcome Sanger Institute and Medicines Discovery Catapult (MDC) have today launched Genomics Nation, showcasing the strength, breadth and opportunity of the UK’s genomics sector for investors, patients and the UK economy.